Vaccine and Adjuvant Immunogenicity

The MIMIC® System predicts the reactogenicity and immunogenicity of antigens, adjuvants, and vaccines. In contrast with animal models, the MIMIC® System is high-throughput (thousands of samples per month), predicts a human response (which may differ significantly from an animal response), and captures human diversity (using cells from donors selected for ethnicity, age, gender, prior exposure, and other factors determined by the customer).

For this MIMIC® application, the Peripheral Tissue Equivalent (PTE) module alone is used to model innate immune responses. Adaptive immune responses are modeled with the Lymphoid Tissue Equivalent (LTE) module paired with the PTE module. The vaccine candidate is administered to the PTE module and the LTE module depending on the formulation. After the antigen-presenting cells have become activated, the activated cells are removed from the PTE module and placed into the LTE module.

In the LTE module, the antigen-presenting cells induce antigen-specific cell expansion and cytokine production for T cells, and expansion, differentiation, and production of antigen-specific antibodies for B cells. The results are measured with standard immunological tests, including cytokine generation, cell proliferation, cell phenotype analysis, and antibody levels.

We have tested this application with commercially available vaccines for tetanus toxoid (Tripedia® DTaP vaccine), influenza (trivalent inactivated – Fluviron®, Fluzone®), yellow fever (YF-VAX®) and hepatitis B (Recombivax HB®). Read our case studies for more details.

These studies may use as few as five to ten donors to obtain preliminary results. However, to capture the full diversity of a target population, a study may use 20-50 or more donors.

The timeline for this type of study is 3-6 months, depending on the number of donors and the types of analysis desired by the customer. The cost of the study depends on the scope of the project and the analysis needed.